共 50 条
- [1] Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusionEXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1265 - 1274Storandt, Michael H.Jin, ZhaohuiMahipal, Amit
- [2] A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)DeLeon, ThomasAlberts, Steven R.McWilliams, Robert R.Hubbard, Joleen MarieAhn, Daniel H.Bekaii-Saab, Tanios S.Mody, KabirRoberts, Lewis R.Salomao, MarcelaKipp, BenjaminHalfdanarson, Thorvardur RagnarMurtaza, MuhammedRamanathan, Ramesh K.Dueck, Amylou C.Borad, Mitesh J.
- [3] FGFR2 fusion in resectable intrahepatic cholangiocarcinoma patientsANNALS OF ONCOLOGY, 2020, 31 : S267 - S267Xu, S.Zheng, Y.Gong, W.Li, B.Wang, Y.Li, H.Zhao, S.Shi, X.Zhang, L.
- [4] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaCANCER DISCOVERY, 2017, 7 (03) : 252 - 263Goyal, LipikaSaha, Supriya K.Liu, Leah Y.Siravegna, GiuliaLeshchiner, IgnatyAhronian, Leanne G.Lennerz, Jochen K.Vu, PhuongDeshpande, VikramKambadakone, AvinashMussolin, BenedettaReyes, StephanieHenderson, LauraSun, Jiaoyuan ElisabethVan Seventer, Emily E.Gurski, Joseph M., Jr.Baltschukat, SabrinaSchacher-Engstler, BarbaraBarys, LouiseStamm, ChristelleFuret, PascalRyan, David P.Stone, James R.Iafrate, A. JohnGetz, GadPorta, Diana GrausTiedt, RalphBardelli, AlbertoJuric, DejanCorcoran, Ryan B.Bardeesy, NabeelZhu, Andrew X.
- [5] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patientsCANCER RESEARCH, 2017, 77Goyal, LipikaSaha, Supriya K.Liu, Leah Y.Siravegna, GiuliaLeshchiner, IgnatyAhronian, Leanne G.Lennerz, Jochen K.Phuong VuMussolin, BenedettaReyes, StephanieFuret, PascalIafrate, A. JohnGetz, GadPorta, Diana G.Tiedt, RalphBardelli, AlbertoJuric, DejanCorcoran, Ryan B.Bardeesy, NabeelZhu, Andrew X.
- [6] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinomaANNALS OF ONCOLOGY, 2021, 32 : S379 - S379Huang, X-W.Shi, G-M.Zhang, T.Bao, L-Q.Wen, T-F.Zhang, B.Peng, T.Zhao, H.Kuang, M.Wang, W-L.Ran, J-H.Liu, Y-B.Gong, W.Mou, H-B.Luo, Y.Wang, Y.Sun, H.Fan, J.Liu, L-X.Dai, M.
- [7] New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangementBULLETIN DU CANCER, 2021, 108 (05) : 446 - 447Delaye, MatthieuPernot, Simon
- [8] FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune SignaturesCLINICAL CANCER RESEARCH, 2022, 28 (24) : 5431 - 5439Sridharan, VishwajithNeyaz, AzfarChogule, AbhijitBaiev, IslamReyes, StephanieFritcher, Emily G. BarrLennerz, Jochen K.Sukov, WilliamKipp, BenjaminTing, David T.Deshpande, VikramGoyal, Lipika
- [9] FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To SorafenibONCOTARGETS AND THERAPY, 2019, 12 : 9303 - 9307Ying, XihuiTu, JianfeiWang, WenxianLi, XingliangXu, ChunweiJi, Jiansong
- [10] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expressionJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)Morizane, ChigusaUeno, MakotoIoka, TatsuyaTajika, MasahiroIkeda, MasafumiYamaguchi, KenseiHara, HirokiYabusaki, HiroshiMiyamoto, AtsushiIwasa, SatoruMuto, ManabuTakashima, TsutomuMinashi, KeikoKomatsu, YoshitoNishina, TomohiroNakajima, Takako EguchiSahara, TakatoshiFunasaka, SetsuoYashiro, MasakazuFuruse, Junji